Statins markedly potentiate aminopeptidase inhibitor activity against (drug-resistant) human acute myeloid leukemia cells

Abstract

Aim: This study aimed to decipher the molecular mechanism underlying the synergistic effect of inhibitors of the mevalonate-cholesterol pathway (i.e., statins) and aminopeptidase inhibitors (APis) on APi-sensitive and -resistant acute myeloid leukemia (AML) cells.

Methods: U937 cells and their sublines with low and high levels of acquired resistance to (6S)-[(R)-2-((S)-Hydroxy-hydroxycarbamoyl-methoxy-methyl)-4-methyl-pentanoylamino]-3,3 dimethyl-butyric acid cyclopentyl ester (CHR2863), an APi prodrug, served as main AML cell line models. Drug combination effects were assessed with CHR2863 and in vitro non-toxic concentrations of various statins upon cell growth inhibition, cell cycle effects, and apoptosis induction. Mechanistic studies involved analysis of Rheb prenylation required for mTOR activation.

Results: A strong synergy of CHR2863 with the statins simvastatin, fluvastatin, lovastatin, and pravastatin was demonstrated in U937 cells and two CHR2863-resistant sublines. This potent synergy between simvastatin and CHR2863 was also observed with a series of other human AML cell lines (e.g., THP1, MV4-11, and KG1), but not with acute lymphocytic leukemia or multiple solid tumor cell lines. This synergistic activity was: (i) specific for APis (e.g., CHR2863 and Bestatin), rather than for other cytotoxic agents; and (ii) corroborated by enhanced induction of apoptosis and cell cycle arrest which increased the sub-G1 fraction. Consistently, statin potentiation of CHR2863 activity was abrogated by co-administration of mevalonate and/or farnesyl pyrophosphate, suggesting the involvement of protein prenylation; this was experimentally confirmed by impaired Rheb prenylation by simvastatin.

Conclusion: These novel findings suggest that the combined inhibitory effect of impaired Rheb prenylation and CHR2863-dependent mTOR inhibition instigates a potent synergistic inhibition of statins and APis on human AML cells.

Keywords

Aminopeptidase / statins / mevalonate pathway / carboxyl esterase / Rheb / mTOR

References

[1] Anderson KC.The 39th David A. Karnofsky Lecture: bench-to-bedside translation of targeted therapies in multiple myeloma.J Clin Oncol2012;30:445-52 PMCID:PMC4800820

[2] Niewerth D,Cloos J,Kaspers G.Proteasome inhibitors in acute leukemia.Expert Rev Anticancer Ther2013;13:327-37

[3] Hitzerd SM,Ossenkoppele G,Peters GJ.Positioning of aminopeptidase inhibitors in next generation cancer therapy.Amino Acids2014;46:793-808

[4] Chen Q,Ge P,Chen X.Ubenimex combined with pemetrexed upregulates SOCS1 to inhibit lung adenocarcinoma progression via the JAK2-STAT3 signaling pathway.Dis Markers2022;2022:5614939 PMCID:PMC9250433

[5] Krige D,Bawden LJ.CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.Cancer Res2008;68:6669-79

[6] Cortes J,Yee K.Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study.Lancet Oncol2013;14:354-62 PMCID:PMC5557006

[7] Smith EM,Walker BA.The combination of HDAC and aminopeptidase inhibitors is highly synergistic in myeloma and leads to disruption of the NFκB signalling pathway.Oncotarget2015;6:17314-27 PMCID:PMC4627310

[8] Shafer D.Update on rational targeted therapy in AML.Blood Rev2016;30:275-83 PMCID:PMC4956515

[9] Walter RB,Wierzbowska A.Measurable residual disease as a biomarker in acute myeloid leukemia: theoretical and practical considerations.Leukemia2021;35:1529-38

[10] Jenkins C,Krige D,Burnett A.Aminopeptidase inhibition by the novel agent CHR-2797 (tosedostat) for the therapy of acute myeloid leukemia.Leuk Res2011;35:677-81

[11] Löwenberg B,Ossenkoppele GJ.Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia.J Clin Oncol2010;28:4333-8

[12] DiNardo CD.Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.Expert Opin Investig Drugs2014;23:265-72

[13] DiNardo CD.New treatment for acute myelogenous leukemia.Expert Opin Pharmacother2015;16:95-106

[14] Mawad R,Hendrie P.Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.Br J Haematol2016;172:238-45

[15] Lee S,Edirisinghe B.Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy.Leuk Lymphoma2021;62:498-500

[16] Dennis M,Hills R.National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working GroupA randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.Br J Haematol2021;194:298-308

[17] Visani G,Dennis M.Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML.Blood Adv2020;4:5040-9 PMCID:PMC7594404

[18] Janssen J,Manz M.Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.Cancers2021;13:672 PMCID:PMC7914531

[19] Moore HE,Smith EM.Aminopeptidase inhibition as a targeted treatment strategy in myeloma.Mol Cancer Ther2009;8:762-70

[20] Reid AH,Attard G.A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.Clin Cancer Res2009;15:4978-85

[21] van Herpen CM,de Jonge M.A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours.Br J Cancer2010;103:1362-8 PMCID:PMC2990605

[22] Verbrugge SE,Assaraf YG.Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR.Oncotarget2016;7:5240-57 PMCID:PMC4868683

[23] Zhao B,St Clair RW,Ghosh S.Redistribution of macrophage cholesteryl ester hydrolase from cytoplasm to lipid droplets upon lipid loading.J Lipid Res2005;46:2114-21

[24] Ghosh S,Bie J.Macrophage cholesteryl ester mobilization and atherosclerosis.Vascul Pharmacol2010;52:1-10 PMCID:PMC2823947

[25] Li HY,Willman CL,Banker DE.Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.Blood2003;101:3628-34

[26] Wong WW,Minden MD.HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis.Leukemia2002;16:508-19

[27] Banker DE,Li HY,Appelbaum FR.Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells.Blood2004;104:1816-24

[28] Xia Z,Wong WW,Minden MD.Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells.Leukemia2001;15:1398-407

[29] der Weide K, Korthuis PM, Kuipers F, de Vries EG, Vellenga E. Heterogeneity in simvastatin-induced cytotoxicity in AML is caused by differences in Ras-isoprenylation.Leukemia2012;26:845-8

[30] Sassano A,Antico G.Suppressive effects of statins on acute promyelocytic leukemia cells.Cancer Res2007;67:4524-32

[31] Burke LP.Statins induce lethal effects in acute myeloblastic leukemia [corrected] cells within 72 hours.Leuk Lymphoma2008;49:322-30 PMCID:PMC2430172

[32] Jonge-Peeters SD, van der Weide K, Kuipers F, Sluiter WJ, de Vries EG, Vellenga E. Variability in responsiveness to lovastatin of the primitive CD34+ AML subfraction compared to normal CD34+ cells.Ann Hematol2009;88:573-80

[33] Kornblau SM,Stirewalt D.Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin + high-dose Ara-C: a phase 1 study.Blood2007;109:2999-3006 PMCID:PMC1852228

[34] Dai Y,Chen S,Dent P.Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation.Blood2007;109:4415-23 PMCID:PMC1885487

[35] Needham LA,Bawden LJ.Drug targeting to monocytes and macrophages using esterase-sensitive chemical motifs.J Pharmacol Exp Ther2011;339:132-42

[36] van Luijn MM,Thompson JA.Class II-associated invariant chain peptide down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T-cell responses.Haematologica2010;95:485-93 PMCID:PMC2833080

[37] Hooijberg JH,Kool M.Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2.Cancer Res1999;59:2532-5

[38] Westerhof GR,Schornagel JH,Peters GJ.Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein.Cancer Res1995;55:3795-802

[39] Verbrugge SE,Dijkmans BA.Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis.J Pharmacol Exp Ther2012;341:174-82

[40] Scheffer GL,Heijn M et al.Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies.Cancer Res2000;60:5269-77

[41] Ifergan I,Assaraf YG.Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.Cancer Res2005;65:10952-8

[42] Bijnsdorp IV,Fukushima M,Gokoel S.Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines.Cancer Sci2010;101:440-7

[43] Bijnsdorp IV,Peters GJ.Analysis of drug interactions.Methods Mol Biol2011;731:421-34

[44] Valeriote F.Synergistic interaction of anticancer agents: a cellular perspective.Cancer Chemother Rep1975;59:895-900

[45] Ota K.Clinical trials of bestatin for leukemia and solid tumors.Biotherapy1992;4:205-14

[46] Berndt N,Sebti SM.Targeting protein prenylation for cancer therapy.Nat Rev Cancer2011;11:775-91 PMCID:PMC4037130

[47] Thurnher M,Nussbaumer O.Regulation of mevalonate metabolism in cancer and immune cells.Biochim Biophys Acta2013;1831:1009-15

[48] Greenwood J,Zamvil SS.Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.Nat Rev Immunol2006;6:358-70 PMCID:PMC3842637

[49] Zoncu R,Efeyan A,Sancak Y.mTORC1 senses lysosomal amino acids through an inside-out mechanism that requires the vacuolar H⁺-ATPase.Science2011;334:678-83 PMCID:PMC3211112

[50] Jewell JL,Guan KL.Amino acid signalling upstream of mTOR.Nat Rev Mol Cell Biol2013;14:133-9 PMCID:PMC3988467

[51] Dibble CC.Signal integration by mTORC1 coordinates nutrient input with biosynthetic output.Nat Cell Biol2013;15:555-64 PMCID:PMC3743096

[52] Thurnher M,Gruenbacher G.Novel aspects of mevalonate pathway inhibitors as antitumor agents.Clin Cancer Res2012;18:3524-31

[53] Wu J,Khosravi F,Penn LZ.Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis.Cancer Res2004;64:6461-8

[54] Ahmed TA,Leggas M.Simvastatin interacts synergistically with tipifarnib to induce apoptosis in leukemia cells through the disruption of RAS membrane localization and ERK pathway inhibition.Leuk Res2014;38:1350-7 PMCID:PMC5628615

[55] Dimitroulakos J,Backway KL et al.Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach.Blood1999;93:1308-18

[56] Condon KJ.Nutrient regulation of mTORC1 at a glance.J Cell Sci2019;132:jcs222570 PMCID:PMC6857595

[57] Advani AS,Copelan E.SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia.Br J Haematol2014;167:233-7 PMCID:PMC4188732

[58] Garciaz S,Collette Y.Targeting regulated cell death pathways in acute myeloid leukemia.Cancer Drug Resist2023;6:151-68 PMCID:PMC10099605

[59] Zhao Y,Peng H.Molecular mechanisms of ferroptosis and its roles in hematologic malignancies.Front Oncol2021;11:743006 PMCID:PMC8582018

[60] Ding H,Yun S.Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells.Haematologica2014;99:60-9 PMCID:PMC4007940

[61] Efeyan A,Sabatini DM.Amino acids and mTORC1: from lysosomes to disease.Trends Mol Med2012;18:524-33 PMCID:PMC3432651

[62] Durán RV.Regulation of TOR by small GTPases.EMBO Rep2012;13:121-8 PMCID:PMC3271343

[63] Groenewoud MJ.Rheb and Rags come together at the lysosome to activate mTORC1.Biochem Soc Trans2013;41:951-5

[64] Castro AF,Clark GJ.Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner.J Biol Chem2003;278:32493-6

[65] Mavrakis KJ,Silva RL.Tumorigenic activity and therapeutic inhibition of Rheb GTPase.Genes Dev2008;22:2178-88 PMCID:PMC2518821

[66] Abu-Remaileh M,Kim C.Lysosomal metabolomics reveals V-ATPase- and mTOR-dependent regulation of amino acid efflux from lysosomes.Science2017;358:807-13 PMCID:PMC5704967

[67] Martelli AM,Chiarini F.The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.Oncotarget2010;1:89-103 PMCID:PMC2911128

[68] Minden MD,Nohynek D.Lovastatin induced control of blast cell growth in an elderly patient with acute myeloblastic leukemia.Leuk Lymphoma2001;40:659-62

[69] van der Spek E,van de Donk NW.Dose-finding study of high-dose simvastatin combined with standard chemotherapy in patients with relapsed or refractory myeloma or lymphoma.Haematologica2006;91:542-45